Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy.
J Ocul Pharmacol Ther. 2012 Apr;28(2):202-4. doi: 10.1089/jop.2011.0140. Epub 2011 Dec 7.
To describe a case of juxtafoveal choroidal neovascularization (CNV) occurring in a patient affected by retinitis pigmentosa (RP), treated with intravitreal bevacizumab over a 12-month follow-up.
A 66 year-old woman referred to our center for visual acuity deterioration was diagnosed as having classic juxtafoveal CNV associated with RP. The patient was treated with intravitreal bevacizumab, and was regularly monitored every month.
At the end of the 12-month follow-up, best corrected visual acuity changed from 20/200 to 20/100 in the affected eye. Five intravitreal bevacizumab injections were required to obtain the stabilization of the CNV.
Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.
描述一例发生在患有色素性视网膜炎(RP)的患者的近黄斑脉络膜新生血管(CNV)病例,该患者接受了长达 12 个月的随访的玻璃体内贝伐单抗治疗。
一名 66 岁女性因视力下降就诊于我院,被诊断为经典型近黄斑 CNV 合并 RP。该患者接受了玻璃体内贝伐单抗治疗,并每月定期进行监测。
在 12 个月的随访结束时,受影响眼的最佳矫正视力从 20/200 提高到 20/100。需要进行 5 次玻璃体内贝伐单抗注射以稳定 CNV。
玻璃体内贝伐单抗在长达 12 个月的随访中,对患有 RP 的患者的近黄斑 CNV 稳定和视力提高有效。需要进一步的研究来确定治疗 RP 合并 CNV 的最佳方法。